InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
1.70%
)
US TECH 100
19,296.40
(
-0.20%
)
Dow Jones
42,025.19
(
1.26%
)
Brent Oil
74.13
(
-0.26%
)
Bitcoin
63,472.67
(
0.83%
)
Post# of 5959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

nsomniyak

Send PM Follow Ignore
Followers 295
Posts 21297
Boards Moderated 18
Alias Born 07/25/2003

nsomniyak

Member Level

Re: bud_fox post# 5635

Wednesday, 08/30/2017 1:20:48 PM

Wednesday, August 30, 2017 1:20:48 PM

Post# of 5959
I have been saying on ST for a while much the same theory as this author puts forward.

As the drugs are not complimentary to each other, to maximize value PTX needs to sell them separately. A buyer for Zohydro, for example, might see the other two drugs as just baggage to be sold off on the cheap, and certainly not worth paying a premium for, while buyers of the other drugs could see Zohydro as baggage. Even if the asset has good revenue, it may not fit with a buyer's sales force and customer base.

If I could afford to buy all of them, I would not need to buy any of them and I sure wouldn't be spending time on the message boards!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up